BMS CCR2 22

BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM) [1][2].

Product Specifications

CAS Number

[445479-97-0]

UNSPSC

12352005

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/bms-ccr2-22.html

Purity

99.27

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NCC(N[C@@H]1[C@H](NC(C2=CC=C(SC)C=C2)=O)CCCC1)=O)C3=CC(C(F)(F)F)=CC=C3NC(NC(C)C)=O

Molecular Formula

C28H34F3N5O4S

Molecular Weight

593.66

References & Citations

[1]Cherney RJ, et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem. 2008 Feb 28;51 (4) :721-4.|[2]Kredel S, et al. High-content analysis of CCR2 antagonists on human primary monocytes. J Biomol Screen. 2011 Aug;16 (7) :683-93.|[3] D'Antoni ML, et al. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 Dec;104 (6) :1241-1252.